News

PharmExec6d
Pfizer’s Hympavzi Demonstartes Significantly Reduced Annualized Bleeding Rates in Hemophilia
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
Applied Clinical Trials Online6d
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Fierce Pharma6d
Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Pfizer’s HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
Pfizer's Hympavzi Hits Key Goals in Hemophilia With Inhibitors
Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.